segunda-feira, 9 de setembro de 2013

Doenças de pele- Foliculite

O que é?
Infecção dos folículos pilosos causadas por bactérias do tipo estafilococos. A invasão bacteriana pode ocorrer espontaneamente ou favorecida pelo excesso de umidade ou suor, raspagem dos pelos ou depilação.
Atinge crianças e adultos podendo surgir em qualquer localização onde existam pelos, sendo frequente na área da barba (homens) e na virilha (mulheres).
Manifestações clínicas
Quando superficial, a foliculite caracteriza-se pela formação de pequenas pústulas ("bolhinhas de pus") centradas por pelo com discreta vermelhidão ao redor. Alguns casos não apresentam pus, aparecendo apenas vermelhidão ao redor dos pelos. Quando as lesões são mais profundas, formam-se lesões elevadas e avermelhadas que podem ter ponto amarelo (pus) no centro. Pode haver dor e coceira no local afetado.

Alguns tipos de foliculite tem características próprias:
  • Foliculite decalvante: neste caso o processo infeccioso leva à atrofia do pelo, deixando áreas de alopécia que se expandem com a progressão periférica da doença.
foliculite decalvante
  • Foliculite da barba: localizada na área da barba, atinge homens adultos, tem característica crônica e, pela proximidade das lesões, pode formar placas avermelhadas, inflamatórias, com inúmeras pústulas e crostas.
  • Foliculite queloideana da nuca: comum em homens jovens afrodescendentes, formando lesões agrupadas que ao cicatrizar deixam cicatrizes endurecidas e queloideanas na região da nuca. Saiba mais...
  • Periporite supurativa: atinge as crianças pequenas e geralmente segue-se à miliária, com pústulas superficiais ou nódulos inflamatórios que acabam por drenar secreção purulenta.
Tratamento
O tratamento é feito com antibióticos de uso local ou sistêmico específicos para a bactéria causadora e cuidados antissépticos, além de evitar fatores predisponentes, como a depilação.
Algumas lesões podem necessitar de drenagem cirúrgica. O dermatologista é o médico mais indicado para o correto diagnóstico e tratamento das foliculites.

sexta-feira, 6 de setembro de 2013

O melanoma maligno

Melanoma maligno é um câncer de pele grave, por produzir metástases com rapidez. O melanoma maligno atinge a melanina que são as células que dão cor à pele, podendo afetar as áreas do corpo expostas ou não ao sol.

Melanoma maligno tem cura

O melanoma maligno tem cura quando ainda não é metastático, por isso é importante que o paciente que tenha tido melanoma assim como seus parentes diretos façam exames de rastreio no dermatologista anualmente para evitar a evolução maligna de alguma lesão da pele.
Este tipo de câncer de pele pode ocorrer em jovens e adultos de todas as idades e raças e atingir além da pele as mucosas da vagina, esôfago, ânus ou intestinos e também os olhos, neste caso chamado melanoma orbital.

Tratamento do melanoma maligno

O tratamento do melanoma maligno é diferenciado de acordo com o estadiamento da lesão.
O tratamento do melanoma maligno graus I e II  se dá com cirurgia para retirada da lesão, para que seja evitado um possível retorno da doença naquele local da pele.
Após a intervenção cirúrgica no local, novos exames deverão ser solicitados a fim de identificar novas lesões, e caso haja metástases na região anteriormente tratada, deverá ser feita nova cirurgia com radioterapia. Classifica-se como melanoma grau III.
Quando se encontram metástases do melanoma maligno em órgãos distantes da lesão inicial, trata-se de um melanoma de grau IV, e neste caso o tratamento é paliativo com quimioterapia e o paciente é considerado incurável.

Fotos do melanoma maligno


Tipos de melanoma maligno 

Os tipos de melanomas malignos podem ser:
  • Melanoma lentiginoso acral: Atinge geralmente as palmas das mãos, solas dos pés e unhas, sendo o melanoma mais comum em negros, asiáticos e hispânicos;
  • Melanoma extensivo superficial: Tipo mais comum de câncer de pele e seu aparecimento em pacientes de pele branca é mais observado;
  • Melanoma nodular:Tem aparência elevada da pele em cores preta azulada e vermelha azulada como mostra a imagem - esse tipo de câncer de pele tende a se espalhar com mais facilidade pelo organismo;
  • Melanoma lentigo maligno: Mais observado em áreas que estão mais expostas ao sol como face,pescoço e dorso das mãos, geralmente em pacientes idosos.

Sintomas do melanoma maligno

Os sintomas do melanoma maligno geralmente não provocam dor e são identificadas através da alteração de tamanho, forma, cor e texturas dos sinais ou manchas existentes na pele.
Alguns dos principais sintomas do melanoma maligno são:
  • Manchas pré existentes que se alteram de tamanho;
  • Aparecimento de manchas ou sinais na pele com contornos irregulares;
  • Coceira num sinal já existente;
  • Sangramento ou liberação de líquidos.

Diagnóstico do melanoma maligno 

O diagnóstico do melanoma maligno é feito através de exames como:
  • Biópsia da lesão;
  • Dermatoscopia, que mapeia as manchas e sinais do corpo;
  • Ressonância magnética;
  • Tomografia computadorizada.
De acordo com o estadiamento do melanoma o médico decidirá qual será o exame de diagnóstico mais eficiente mediante cada caso.

sexta-feira, 30 de agosto de 2013

Técnica do preenchimento cutâneo

Preenchimento cutâneo
O preenchimento cutâneo é uma técnica utilizada para a correção de sulcos, rugas e cicatrizes. Consiste na injeção de substâncias sob a área da pele a ser tratada elevando-a e diminuindo a sua profundidade, com consequente melhora do aspecto.
A técnica, desenvolvida por dermatologistas, pode ser realizada no consultório, sendo um procedimento rápido e que, na maioria das vezes, não necessita nem mesmo de anestesia. Para pessoas mais sensíveis, se desejado, podem ser utilizados anestésicos tópicos, sob a forma de cremes, aplicados 30 a 60 minutos antes do preenchimento, para atenuar a sensação da picada da agulha.
A técnica é muito utilizada para atenuar o sulco nasogeniano (aquele que se acentua com o sorriso e vai do canto do nariz ao canto da boca) ou os sulcos ao redor dos lábios.
Preenchimento do Sulco Naso-Geniano
Também é usada para aumento labial, correção de cicatrizes de acne e reposição volumétrica em áreas do corpo onde ocorre perda de gordura com o envelhecimento.
Correção de cicatrizes de acne
preenchimento cutâneo
Preenchedores temporários e definitivos
Entre as substâncias mais utilizadas para realizar o preenchimento cutâneo estão o ácido hialurônico e o metacrilato.
O ácido hialurônico (Esthelis, Juvederm, Perfectha, Rennova, Restylane, Surgiderm, Teosyhal...) é considerado um dos produtos mais seguros para a realização do preenchimento cutâneo e, por isso, tem sido o mais utilizado dos preenchedores.
Apesar de ser produzido em laboratório, o ácido hialurônico é um componente natural da derme, segunda camada da pele, não causa alergias e dispensa testes prévios. A duração do preenchimento varia de 6 a 12 meses, sendo necessária nova aplicação após este período.
Muito usado para o preenchimento dos sulcos nasogenianos e para aumento dos lábios, o ácido hialurônico também apresenta uma forma mais fluida, para aplicação em rugas finas, como aquelas ao redor dos olhos ou dos lábios (apelidadas de "código de barras") e uma forma para aplicação mais profunda e em maior volume, para recuperação dos contornos faciais.
Uma outra opção de uso é o aumento do volume labial, para mulheres que tem lábios muitos finos ou cujos lábios, com o passar dos anos, perderam volume devido ao envelhecimento.
Já o metacrilato é um preenchedor definitivo. Por não ser reabsorvido pelo organismo, seus resultados são duradouros e é mais utilizado para correção de sulcos profundos e para alteração do contorno corporal. A substância é aplicada mais profundamente e pode ser usada em maior volume.
O metacrilato tem sido largamente utilizado para a correção da lipodistrofia decorrente do tratamento de pacientes com HIV/AIDS.
Preechedores com estímulo à produção de colágeno
Uma outra linha de preenchedores busca o estímulo à produção de colágeno pelo organismo, que será o responsável pelo preenchimento das rugas. Entre eles estão o ácido polilático (Sculptra) e a hidroxiapatita de cálcio (Radiesse).
Os dois produtos também tem sido utilizados para o preenchimento das mãos naquelas pessoas que, com o envelhecimento, perdem gordura deixando depressões entre os tendões dos dedos.
Lipoescultura
Uma variação desta técnica é o auto-enxerto de gordura, na qual retira-se gordura de uma área do corpo onde esteja em excesso (através de lipoaspiração) e injeta-se sob a ruga elevando-a.
Este procedimento é mais trabalhoso, exige anestesia e outros cuidados para a obtenção do material gorduroso a ser injetado. Ideal para aqueles que desejam livrar-se de gorduras extras em áreas localizadas e vão se submeter a uma lipoaspiração. A gordura retirada será então aproveitada para o preenchimento cutâneo. Uma parte da gordura injetada é reabsorvida porém boa parte dela permanece definitivamente no local. A técnica tem sido chamada de lipoescultura.
Colaboração: Dr. Roberto Barbosa Lima - Dermatologista

sexta-feira, 23 de agosto de 2013

Vinte dicas para evitar a oleosidade e o brilho em excesso na pele

Toda pele necessita de cuidados especiais. Principalmente quem tem pele oleosa sabe que é mais difícil cuidar dela, pois sofre com a tendência a acne e excesso de brilho. Certos cuidados são fundamentais para manter a pele oleosa controlada.
Quer ter uma pele livre da oleosidade e do brilho excessivo? A dermatologista Miriam Sabino dá 20 dicas de como manter a pele sempre limpinha e longe das acnes.
1 - Lave muito bem o rosto com sabonete próprio para pele oleosa.
2 - Procure usar um esfoliante para eliminar as células mortas. Uma esfoliação, mesmo que caseira, pode retirar o excesso de sebo da pele, ajuda a eliminar cravos, limpa e diminui a oleosidade do local.
3 - Prefira uma base livre de óleo e que não seja muito líquida.
4 - Lave o rosto cerca de 3 vezes ao dia com produtos indicados para pele oleosa, isso ajuda a limpar os poros e retirar o acumulo de sebo na pele.
5 - Prefira produtos em gel.
6 - Peles com tendência a oleosidade devem usar produtos como protetores solar e hidratantes também em consistência de gel. Produtos em creme devem ser evitados, pois, ajudam a provocar oleosidade na pele.
7 - A limpeza de pele, limpa e renova a pele, diminuindo a oleosidade.
8 - Vá ao dermatologista! Este profissional é especializado em pele, então, ninguém melhor que ele para tratar deste problema.
9 - Passe pó facial para finalizar a maquiagem. O ideal é o mineral, para eliminar a oleosidade e dar o acabamento final. Use pincel, nunca use esponja.
10 - Use sombras compactas de longa duração e que fixam (nunca em creme ou bastão).
11 - Se necessitar de corretivo, prefira os mais secos em pó ou em bastão. Evite os cremosos e líquidos.
12 - Use rímel, lápis ou delineador que sejam a prova d’água.
13 - O blush deve ser em pó, pois regula a oleosidade. Evite os líquidos e cremosos.
14 - Nunca esqueça de remover a maquiagem. Os produtos entopem os poros e podem gerar espinhas.
15 - Tire o cabelo do rosto. Se você usa franja ou vive com o cabelo caindo no rosto, a oleosidade do couro cabeludo se transfere para a pele, que fica sujeita às espinhas.
16 - Algumas vitaminas são capazes de regular a oleosidade, como: A vitamina B, presentes nos cereais e nas carnes magras.
17 - Verduras de cor verde-escura são ricas em Vitamina A, que reduz a produção de sebo.
18 - Tome cuidado com o sol! O sol estimula a produção de sebo.
19 - Evite fast food: o alto teor de sal e iodo tem ação irritante na pele, podendo desencadear ou piorar a acne.
20 - Use sempre protetor solar oil-free gel, pois os cremes estimulam a oleosidade.

segunda-feira, 12 de agosto de 2013

Pele aveludada e brilho feito com gloss são novas tendências


Uma pele bonita é essencial para uma maquiagem que chama a atenção. E a nova tendência para que a pele fique perfeita é maquiá-la com um aspecto aveludado, de acordo com a maquiadora sênior da M.A.C, Fabiana Gomes, que apresentou os novos hits da temporada.

Para deixar a pele com essa aparência de veludo, sem aparentar opacidade, é preciso usar produtos de boa qualidade. “Temos que evitar o aspecto pesado e opaco, a pele tem que ter vida, não pode parecer muito carregada”, diz Fabiana.

O ideal é aplicar uma camada fina de base e passar um ótimo pó, principalmente no centro do rosto: testa, ponta e laterais do nariz e queixo. “Você até pode usar um pincel médio para controlar melhor a aplicação, mas sem colocar muita quantidade de produto de uma vez”, ensina a expert.

Hidratação aparente
A pele tem também um contraste: é aveludada, mas com hidratação, principalmente nas laterais do rosto e no alto das maçãs. “Nas passarelas, vimos esse brilho feito com gloss transparente. No dia a dia podemos usar um hidratante ou um pouquinho de óleo essencial”, explica a maquiadora.

segunda-feira, 15 de julho de 2013

Dicas básicas para ter uma boa pele: hidratação e protetor solar.

Já pensou descobrir a fonte da juventude eterna? Pois é, se manter jovem é o desejo de dez entre dez pessoas. Se não dá para ficar com seus 20 aninhos para sempre, é possível, com a ajuda da tecnologia e dos médicos, manter uma pele bonita. No estúdio, Ana Maria Braga recebe o dermatologista Otávio Macedo para tirar algumas dúvidas sobre rejuvenescimento facial. Para começar, o especialista dá duas dicas básicas: hidratação e uso de protetor solar.

Pés de galinha:
Você tem uma constituição genética para ter mais ou menos "pés de galinha". Eles dependem da movimentação da musculatura na região. Pessoas que têm olhos claros se defendem mais da luz, então, vão ter mais precocemente. Primeiro, hidrate bem essa área e use creme específico para contornos e filtro solar. A toxina botulínica pode ser usada como prevenção.
Só com tratamento resolve a flacidez do pescoço ou tem que fazer cirurgia plástica?
Depende do grau da flacidez. Se for intensa, a cirurgia é indicada. Mas, para flacidez média e moderada, a partir dos 40 anos, você pode usar o aparelho chamado ultrassom microfocado, que atinge a musculatura superficial e dá um efeito de lifting. Quem tem a pele muito fina pode sair do consultório com alguns hematomas, mas volta logo às suas atividades normais.
Quem tem a pele ressecada pode fazer tratamento com ácido?
Existem ácidos que podem ser usados em peles sensíveis. O médico deve ir testando com o paciente. Cosméticos à base de retinol também são indicados. É um tratamento a longo prazo. Ele deve ser aplicado à noite e retirado pela manhã. Após, aplicar filtro solar.
É possível retirar as manchas de sol?
Sim, da seguinte maneira: hidratação correta, uso de toxina botulínica e de ácido hialurônico. Se tiver algumas lesões, podemos tratar com lasers específicos.
Tratamentos em consultórios podem chegar a R$ 7 mil
Os consultórios dos dermatologistas estão cheios de novidades quando o assunto é rejuvenescimento facial. Os tratamentos, porém, são caros, com preços chegando até a R$ 7 mil.
Ultrassom microfocado (deve ser feito uma vez por ano): indicado para flacidez leve e média, custa de R$ 5 mil a R$ 7 mil.
Preenchimento: tratamento para diminuir rugas e marcas de expressão custa R$ 2,2 mil por aplicação.

Laser de clareamento: para amenizar manchas de sol sai por R$ 1,5 mil cada aplicação.
Atenção: Mulheres grávidas ou que estejam amamentando não devem fazer esses tratamentos.

terça-feira, 25 de junho de 2013

CANCER VACCINES

18th September to 19th September 2013, London, United Kingdom

SMi proudly presents the 2nd annual conference on Cancer Vaccines taking place on 18th and 19th September, London. This year’s event aims to focus on innovation and novel strategies within the field, the regulatory environment, and the future direction of cancer vaccines; as well as offering current preclinical and clinical outlook, data, and case studies.

As cancer is still one of the greatest causes of human mortality it is a very attractive target for vaccination. Despite a dramatic increase in research within cancer vaccines in the last decade, there is still a need for more effective therapies to maximise cancer survival rates. Novel strategies for target selection, vaccine design, immunostimulatory therapies, and other biologics are constantly being developed and improved.

The conference, now in its 2nd year, annual Cancer Vaccine conference will examine not only the current clinical data but also the new innovations within the field. This informative event will draw from expert opinions, groundbreaking data, and regulatory factors to look to the future and assess where the field is advancing. This really is a unique event not to be missed.

Benefits of Attending:
Explore innovative and novel strategies, approaches, and vaccines within the field.
Discover future trends, the direction of the field, and combination strategies in both preclinical and clinical situations.
Evaluate the regulatory environment and the subsequent impact on cancer vaccine development.
Consider current trial data, clinical developments, and successful therapeutic vaccines
Learn from successes, failures, and challenges from experts in the field, and apply to optimise vaccine development

Speakers include:
Alex Kudrin, Medical Assessor, Biologicals Licensing, MHRA
Kevin Pollock, Senior Epidemiologist, NHS National Services Scotland
Martin Glennie, Professor of Immunochemistry, University Of Southampton
Pierre van der Bruggen, Group Leader, Ludwig Institute for Cancer Research
Rose-Ann Padua, Research Director, INSERM
Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono

REGISTER ONLINE AT www.smi-online.co.uk/goto/2013cancervaccinesevent4.asp

sexta-feira, 26 de abril de 2013

Why the Anatomy Lab Remains a Fixture of Medicine


 For hundreds of years, physicians have been dissecting the dead to learn about the inner workings of the human body.

While the subject matter itself hasn't changed much, the study of anatomy has been steadily advancing — both in terms of the tools available to clinicians and the ways in which educators and students approach the material. Yet amidst these changes, there's no replacement for the hands-on experience of the anatomy lab, physicians say.

Many people think the purpose of the anatomy lab is for students to simply learn the nomenclature for the parts of the body, said Todd Olson, an anatomist at Albert Einstein College of Medicine in New York. This is certainly part of the purpose — "anatomy is the foundation for the language of medicine: the language health-care professionals use for communicating about patients," Olson said. But it's not the only reason. [Image Gallery: The Oddities of Human Anatomy]

quinta-feira, 25 de abril de 2013

Man with hole in stomach revolutionized medicine


A man whose gunshot wound created a window into his stomach enabled scientists to understand digestion.
But the patient, a fur trapper named Alexis St. Martin, also transformed how physiologists studied the body, new research suggests.

People "realized this was a revolutionary approach to doing physiology and medicine. You collect data on the clinical patient and then come to your conclusions," said study co-author Richard Rogers, a neuroscientist at the Pennington Biomedical Research Institute in Baton Rouge, La.

Prior to that, doctors typically decided what was wrong with a patient or how a bodily function worked often based on 1,600-year old medical ideas of Galen before ever setting eyes on them, Rogers said.

The findings were presented Tuesday (April 23) at the Experimental Biology 2013 conference in Boston, Mass.

Gory wound

Physiologist William Beaumont, an army doctor, was stationed in Fort Mackinac in Mackinac Island, Mich., on June 6, 1822, when a fur trapper's gun discharged and accidentally shot 19-year-old trapper Alexis St. Martin in the stomach.

The wound was gory and St. Martin wasn't expected to live out the night.
"He had lung hanging out of his wound," Rogers told LiveScience.
Yet amazingly, Beaumont performed several antiseptic- and anesthesia-free surgeries on St. Martin over several months, and St. Martin eventually recovered.

Window into digestion

St. Martin became fed up with surgery and was left with a fistula, a hole in his stomach through the abdominal wall, which left it open to view. (The strong stomach acid essentially disinfected the wound from the inside out, making it safe to not sew it up.)

Because St. Martin couldn't work as a fur trapper anymore, Beaumont hired him as handyman. The daily task of cleaning the fistula gave Beaumont an idea: perhaps he could watch the process of digestion at work.
So for the next several years, Beaumont recorded everything that went into St. Martin's stomach, then painstakingly described what went on inside. He also took samples of gastric secretions and sent them to chemists of the day for analysis an unheard of task at the time.

His precise observations led him to conclude that the stomach's strong hydrochloric acid, along with a little movement, played key roles in digestion, rather than the stomach grinding food up as some physiologists of the day believed.

"He was the first one to observe digestive processes going on in real time," Rogers said.
He was also the first to notice that St. Martin's digestion slowed when he was feverish, making the first link between digestive processes and disease, Rogers said.
Revolutionary approach

The findings paved the way for modern physiology, where observations guided conclusions, not vice versa, Rogers said.

The study also ushered in some of the first controlled animal experiments by physiologists who realized they could make faster headway by performing fistula operations in animals.
For instance, Beaumont's experiments inspired the famous Russian physiologist Ivan Pavlov to conduct fistula operations in dogs. It was this window into digestion that spurred Pavlov to make his famous conclusions that classical conditioning could spur dogs to salivate on cue, Rogers said.
St. Martin, meanwhile, lived to the ripe old age of 83, going back to fur trapping for a while and eventually becoming a farmer.

quarta-feira, 24 de abril de 2013

Strange Tales From the Frontiers of Resuscitation Medicine


Sam Parnia practices resuscitation medine. In other words, he helps bring people back from the dead — and some return with stories. Their tales could help save lives, and even challenge traditional scientific ideas about the nature of consciousness.

“The evidence we have so far is that human consciousness does not become annihilated,” said Parnia, a doctor at Stony Brook University Hospital and director of the school’s resuscitation research program. “It continues for a few hours after death, albeit in a hibernated state we cannot see from the outside.”

Resuscitation medicine grew out of the mid-twentieth century discovery of CPR, the medical procedure by which hearts that have stopped beating are revived. Originally effective for a few minutes after cardiac arrest, advances in CPR have pushed that time to a half-hour or more.

New techniques promise to even further extend the boundary between life and death. At the same time, experiences reported by resuscitated people sometimes defy what’s thought to be possible. They claim to have seen and heard things, though activity in their brains appears to have stopped.

It sounds supernatural, and if their memories are accurate and their brains really have stopped, it’s neurologically inexplicable, at least with what’s now known. Parnia, leader of the Human Consciousness Project’s AWARE study, which documents after-death experiences in 25 hospitals across North America and Europe, is studying the phenomenon scientifically.

Parnia discusses his work in the new book Erasing Death: The Science That Is Rewriting the Boundaries Between Life and Death. Wired talked to Parnia about resuscitation and the nature of consciousness.


Wired: In the book you say that death is not a moment in time, but a process. What do you mean by that?

Sam Parnia: There’s a point used to define death: Your heart stops beating, your brain shuts down. The moment of cardiac arrest. Until fifty years ago, when CPR was developed, when you reached this point, you couldn’t come back. That led to the perception that death is completely irreversible.

But if I were to die this instant, the cells inside my body wouldn’t have died yet. It takes time for cells to die after they’re deprived of oxygen. It doesn’t happen instantly. We have a longer period of time than people perceive. We know now that when you become a corpse, when the doctor declares you dead, there’s still a possibility, from a biological and medical perspective, of death being reversed.

Of course, if someone dies and you leave them alone long enough, the cells become damaged. There’s going to be a time when you can’t bring them back. But nobody knows exactly when that moment is. It might not just be in tens of minutes, but in over an hour. Death is really a process.

Wired: How can people be brought back from death?
Parnia: Death is, essentially, the same as a stroke, and that’s especially true for the brain. A stroke is some process that stops blood flow from getting into the brain. Whether it’s because the heart stopped pumping, or there was a clot that stopped blood flow, the cells don’t care.

Brain cells can be viable for up to eight hours after blood flow stops. If doctors can learn to manipulate processes going on in cells, and slow down the rate at which cells die, we could go back and fix the problem that caused a person to die, then re-start the heart and bring them back. In a sense, death could become reversible for conditions for which treatments become available.

If someone dies of a heart attack, for example, and it can be fixed, then in principle we can protect the brain, make sure it doesn’t experience permanent cellular death, and re-start the heart. If someone dies of cancer, though, and that particular cancer is untreatable, then it’s futile.

Wired: Are you talking about bringing people to life days or weeks or even years after they’ve died?

Parnia: No. This is not cryogenics. When you die, most of your cell death occurs through apoptosis, or programmed cell death. If your body is cold, the chemical reactions underlying apoptosis are slower. Making the body cold slows the rate at which cells decay. But we’re talking about chilling, not freezing. The process of freezing will damage cells.

Wired: You also study near-death experiences, but you have a different term for it: After-death experience.

Parnia: I decided that we should study what people have experienced when they’ve gone beyond cardiac arrest. I found that 10 percent of patients who survived cardiac arrests report these incredible accounts of seeing things.

When I looked at the cardiac arrest literature, it became clear that it’s after the heart stops and blood flow into the brain ceases. There’s no blood flow into the brain, no activity, about 10 seconds after the heart stops. When doctors start to do CPR, they still can’t get enough blood into the brain. It remains flatlined. That’s the physiology of people who’ve died or are receiving CPR.

Not just my study, but four others, all demonstrated the same thing: People have memories and recollections. Combined with anecdotal reports from all over the world, from people who see things accurately and remember them, it suggests this needs to be studied in more detail.

Wired: One of the first after-death accounts in your book involves Joe Tiralosi, who was resuscitated 40 minutes after his heart stopped. Can you tell me more about him?

Parnia: I wasn’t involved in his care when he arrived at the hospital, but I know his doctors well. We’d been working with the emergency room to make sure they knew the importance of starting to cool people down. When Tiralosi arrived, they cooled him, which helped preserve his brain cells. They found vessels blocked in his heart. That’s now treatable. By doing CPR and cooling him down, the doctors managed to fix him and ensure that he didn’t have brain damage.

When Tiralosi woke up, he told nurses that he had a profound experience and wanted to talk about it. That’s how we met. He told me that he felt incredibly peaceful, and saw this perfect being, full of love and compassion. This is not uncommon.

People tend to interpret what they see based on their background: A Hindu describes a Hindu god, an atheist doesn’t see a Hindu god or a Christian god, but some being. Different cultures see the same thing, but their interpretation depends on what they believe.

segunda-feira, 22 de abril de 2013

Alternative Medicine May Help Control Costs


Use of complementary and alternative (CAM) treatment strategies has become a recognized option for many medical and mental conditions.

For chronic illness, CAM is often blended with traditional medical care as people believe the therapies help them better manage their lives.

A new major Nordic research project has scientifically mapped the use of alternative treatment among multiple sclerosis patients.

Researchers from five Nordic countries find that CAM users are often affluent, younger, and more educated than the general population. Also, young women often use CAM as a reflection of lifestyle choices.

As health care costs skyrocket across the world, expanded use of CAM potentially provides a cost-effective option for better care management.

Researchers found that in the case of multiple sclerosis (MS), people use alternative treatments such as dietary supplements, acupuncture and herbal medicine to facilitate their lives with this chronic disease.

“What we see is that patients do not usually use alternative treatments for treating symptoms, but as a preventative and strengthening element,” said Lasse Skovgaard, Ph.D., who has been involved in conducting the questionnaire-based study among 3,800 people with MS in Denmark, Sweden, Norway, Finland and Iceland.

Multiple sclerosis is a chronic disease which attacks the central nervous system, and which can lead to a loss of mobility and sight. Multiple sclerosis, as any chronic illness, is often accompanied by depression and anxiety.

The incidence of MS is increasing across the world with Denmark experiencing a high prevalence of the disease. Together with researchers from the five other Nordic countries, Skovgaard has spent three years gathering the new data.

“Within the field of health research, it is often a question of studying the extent to which a particular type of drug affects a particular symptom. However, it is equally as important to look at how people with a chronic disease, for example, use different treatments to cope with their situation.

“Here, MS patients offer valuable experience. Their experiences constitute a knowledge bank which we must access and learn from,” he says.

“There is a lot of talk about ‘self-care competence’, in other words patients helping themselves to get their lives to function. Here, many people with a chronic disease find they benefit from using alternative treatments, so we should not ignore this possibility,” said Skovgaard.

Furthermore, learning why patients choose particular treatments is important in relation to improving patient safety because of the possible risks involved in combining conventional and alternative medicine.

According to a 2010 Health and Sickness Study from the Danish National Institute of Public Health (NIPH), one in four Danes say that they have tried one or more types of alternative treatments within the past twelve months.

Among MS patients, the use of alternative medicine has been growing steadily over the past 15 years. In the researchers’ latest study, more than half of the respondents say that they either combine conventional and alternative medicine or only use alternative medicine.

“We cannot ignore the fact that people with chronic disease use alternative treatments to a considerable extent, and that many of them seem to benefit from doing so. It doesn’t help to only judge this from a medical point of view or say that alternative treatments are nonsense – rather, we must try to understand it.”

The study shows that, among MS patients using alternative treatments, there is a significantly bigger proportion of people with a high level of education compared to those who do not use alternative treatments. There is also a larger proportion of highly paid people and of younger women.

“Some critics are of the opinion that when alternative treatments are so popular, it is because they appeal to naïve people looking for a miraculous cure. But our results indicate that it is primarily the well-educated segment that is subscribing to alternative treatments. And that using alternative treatments is part of a lifestyle choice,” said Skovgaard.

He hopes that the new knowledge will improve communication regarding how the chronically ill use alternative treatments in combination with conventional medicine.

“We see that so many people are combining conventional medicine with alternative treatment that it should be taken seriously by the health service. Until now, there hasn’t been much focus on the doctor-patient dialogue in relation to the alternative methods used by the chronically ill to manage their lives,” says Skovgaard.

Additional research will assess how patients perceive the risks associated with using alternative medicine and explore why some patients turn their backs completely on conventional medicine.

sexta-feira, 19 de abril de 2013

X-ray vision: how a chance discovery revolutionised medicine

Katie Maggs of London's Science Museum and Liz Parvin of the Open University discuss how a German physicist called Wilhelm Roentgen stumbled upon a completely unknown form of electromagnetic radiation in 1895 … and why they believe the X-ray machine was such a worthy winner of the museum's 20th Century Icons public vote. Few discoveries can have brought such far-reaching benefits for humanity as X-rays, not just in medicine but also molecular biology, materials and astronomy. The device on display at the museum was built by Russell Reynolds in the UK just months after Roentgen's discovery


quarta-feira, 17 de abril de 2013

Regenerating the future of medicine


Regenerative medicine is poised to dramatically alter conventional methods of treatment, shifting the focus away from symptoms and targeting the specific causes of different defects.

Within this field, adult stem cell research has already established itself as a concrete option for curing several diseases and researchers are excited by the possibilities opening up before them.

Professor Silviu Itsecu, founder and CEO of Mesoblast, a regenerative medicine company, expanded on the potential opportunities: “We’re developing products now based on the stem cells that could allow them to be delivered very simply by an intravenous injection, taking advantage of the properties that they will home (take back) to this specific damaged tissue that we’re trying to target.”

He gave a couple of examples: “An inflamed joint in patients with rheumatoid arthritis, these cells will find themselves going to the inflamed joint and selectively treating that joint. Otherwise, we’re looking at lung disease. So in certain inflammatory lung diseases the cells from simple intravenous injection will find their way straight to the inflamed lung and be able to do their thing (their job) locally, without actually getting to other healthy tissues where we don’t want them to go.”

And yet, whilst the prospect of cell replacement is increasingly acknowledged, its current limitations are also worth noting. Sir John Gurdon, the 2012 Nobel prize winner for Physiology or Medicine, has been one of those eager to stress this point;

“Where people need one kind of cell type, I think that’s a very good promise. It’s quite another thing to say ‘We will replace a whole heart or a whole brain’, that’s complicated, but to replace individual cell types seems very good prospects,” he told euronews.

One party keen on progress, is the Catholic Church, which controversially championed the new technology as an ethical alternative to embryo stem cells research.

terça-feira, 16 de abril de 2013

"Dirty" Cancer Fighter: Medicine's Next Big Thing?


A single cell causes it and it kills millions of people around the world every year

We have a lot of ways to treat cancer once it forms, but there might be a new way to prevent it.

It's most famous for its statues, "called Moai," but a drug discovered in the dirt among the Easter Island icons back in the 70's, could be the answer to preventing cancer.

"This drug has had a lot of lives," said Z. Dave Sharp, PhD, Professor of Molecular Medicine at the UT Health Science Center at San Antonio.

Dr. Dave Sharp says rapamycin was first used as a fungicide. Now it's used as anti-cancer therapy and an immunosuppressant.

"It can prevent transplant rejection," Dr. Sharp said.

A few years ago, he got the idea it might help extend life too.

"And everybody said oh that's a crazy idea," Dr. Sharp explained.

However, studies showed mice given the drug had their lives extended by up to 30 percent.

"They look younger. They act younger. They're more mobile," Dr. Sharp said.

On top of that Tyler Curiel, MD, MPH, Professor of Medicine at the UT Health Science Center at San Antonio, told ABC30, "The mice that got rapamycin appeared to have their cancers prevented."

Now they're giving mice cancer-causing chemicals. The idea is to find out if the drug is boosting their immunity, so their immune systems can kill cancer cells as soon as they appear.

"There's a lot of evidence that it boosts your immunity," Dr. Curiel said.

If it really does prevent the disease in these guys, "Perhaps eventually people will be able to take this drug," Dr. Sharp explained.

A two year, 450 thousand dollar grant from the National Cancer Institute is helping fund the work. Dr. Curiel says if the drug does prove to prevent cancer in mice, human trials could start in about two years.

sexta-feira, 12 de abril de 2013

Quebec sees renewed focus on family medicine


With pressure from the Quebec government to produce an equal number of medical residents in family medicine and specialties by 2014-15, McGill University’s medical school — like many in the province — is moving toward creating a curriculum that will try to generate some excitement about a field that is sometimes viewed as less interesting and lucrative than medical specialties.

When McGill started working on a revision of its medical curriculum, only 17 per cent of its students were going into family medicine. Now it’s up to 37 per cent, similar to other big universities like the University of Toronto, but Quebec is increasing the number of residencies it makes available in family medicine and lowering that of specialties, so McGill has moved to meet the demand.

However, some physicians who are worried about the repercussions of the new curriculum seem to feel a push for family medicine is incompatible with the research excellence for which McGill is renown.

Not so, said McGill dean of medicine, Dr. David Eidelman.

“We already have quite excellent research in family medicine and McGill has Canada’s only graduate program in family medicine,” he said. “We’re still graduating a majority of specialists, but society doesn’t only need specialists.”

So McGill will be moving ahead with a revamped curriculum this fall that will give students more exposure to family physicians and family medicine right from the beginning of their medical education, in hopes of encouraging them to choose that direction.

“One way of encouraging more students to select family medicine as a career is to have more generalists and family physicians teaching the undergraduate curriculum so they interact and see them as role models,” said Dr. Nick Busing, president of the Association of Faculties of Medicine of Canada. “A lot of this is driven by the need in the community for more family doctors.”

And the approach is not new. Quebec’s other medical schools are already headed in this direction.

“There is pressure from the government to address this,” said Dr. Jean Pelletier, director of the family medicine and emergency department for the Université de Montréal. “About 30 per cent of Quebecers don’t have access to a family doctor so there is still a big deficit.”

He said U de M has already started working to “create excitement” about family medicine, and the same is true at the Université Laval as well.

Laval’s medical school has already built a new curriculum around promoting more interest in family medicine, said Dr. Guy Béland, director of the family and emergency medicine department.

“We are definitely trying to give students more exposure to family medicine from the first to the fourth year of the program,” he said.

And it’s paying off. This year, more than 50 per cent of Laval’s students chose a family medicine residency, meaning the university has already achieved the goal set out by the government for next year.

“This is the first time we passed 50 per cent and we’re very proud of that,” said Béland. “Now we have to see if we can maintain it.”


quarta-feira, 10 de abril de 2013

Cardiff University dean of medicine cleared of research misconduct


Professor Paul Morgan and other members of his research group were cleared by a formal investigation panel.
But four allegations of image manipulation in articles were upheld against a former staff member.
Prof Morgan, who researches diseases, said the actions of one individual had a "profound effect" on his reputation.
A clinical academic, the professor heads a team which Cardiff University's website said is "internationally recognised for its expertise and contribution to the field of complement biology".
He remained in his post during the investigation by the panel, which was chaired by a former Cardiff circuit judge.
"Throughout this episode, I have maintained my innocence, and that of my research team, in the face of allegations of research misconduct," he said.
"I am pleased that the independent panel has rejected all allegations against me and concluded that there was no case to answer.

Start Quote

The episode has been extremely upsetting - not only for me personally, but also for friends, family, colleagues - and particularly, my research team”
Prof Paul Morgan
"The episode has been extremely upsetting, not only for me personally, but also for friends, family, colleagues - and particularly, my research team."
Prof Morgan said he believed the allegations needed investigation "to ensure the highest academic standards are maintained".
"The university has examined more than 40 published articles in relation to my research group and no additional findings of academic misconduct were made.
"However it is a matter of deep regret that the actions of one individual has had such a profound effect on the academic reputations of my colleagues and myself."
He added that after eight difficult months he was now looking on focusing his energies on undertaking research that will help with the treatment of human diseases.
The inquiry rejected all allegations against Prof Morgan and members of his research team, but upheld four allegations of misconduct against the former university employee.
The panel also said that Prof Morgan - the co-author of the four articles in question - would not have been aware that the individual had included manipulated images in the articles.
Cardiff University said it took allegations of academic research misconduct against staff extremely seriously.
"The panel did find that allegations of data manipulation against a former member of university staff were substantiated and recommends that protocols are put in place to ensure that data and original image files are in future viewed and assessed prior to submission for publication," a spokesperson said.
"Cardiff University accepts these findings and recommendations and will now take action to put in place procedures to ensure that incidents of this sort do not recur."

terça-feira, 9 de abril de 2013

Obamacare made medicine dangerous to your health


Safety is always cited as a reason to involve government in medicine. But those of us on the front lines, those of us actually seeing patients, realize that government cannot insure your safety – and generally makes things worse.

Recently we and every other hospital and clinic which accepts Medicare payment has implemented electronic medical records. Electronic medical records were forced on us as part of Medicare and Obamacare, purportedly to help avoid redundancy of testing, to make past medical history more available and to make it easier to monitor the disease processes both individually and in aggregate.


Trust me, it does none of these things, but it does make you, the patient, at more risk of gross medical error.

I don’t know any non-university physician who likes electronic medical records. The issues I raise should not be seen as isolated to my facility, nor to my particular brand of EMR (electronic medical records).

In a busy orthopaedic clinic, in order to see patients efficiently, records may be dictated after the patient has left. It is not uncommon to make an error in recording the location of an injury or lesion, mistaking left for right either through dictation error, thinking backwards or transcription error. For example, I see a patient with a broken arm, and accidentally dictate right when it is the left arm that is broken. Thankfully, there are multiple layers of checks and balances to catch such mistakes. With a paper chart, this can easily be corrected on the note so that there is no evidence of the wrong side being recorded – we simply retype the note. Or the error can be crossed out, so the error is still visible, but clearly has been corrected.


Not so with EMR. Once the note is signed off for 24 hours, it cannot be changed. The best that can be done (at least in some systems) is that an addendum can be put in the chart. This little correcting note, for example, “Regarding Mrs. Jones wrist fracture, the injury occurred on the left, not the right as previously noted,” may or may not be stored next to the note with the error. It may or may not be obvious to anyone needing information about the patient. In other words, a physician seeing the patient in the future who is not familiar with the case may read the note, but not the addendum, because he does not know to look for it. It is obvious to any physician, but apparently not to the people who write these programs, that this is a major safety hazard.

The risk of medical error is compounded by the new digital X-ray systems. For decades, ever since X-rays have been used in operating rooms, there has been an industry standard. The X-ray was put up on the view box with left on left, and right on right. As a resident, it was my job to insure that the X-rays were correctly hung. So if I am operating on a left sided lumbar disc, the X-ray picture on the wall mirrors the reality with the ruptured disc on the left.

But in the new digital world, the industry standard is left on right. In other words, in the operating room the new standard for displaying images is backwards from historical precedent and from reality. Now, with a brain lesion, kidney mass, ruptured disc, or fracture on the left, the digital X-ray shows it to the right of the screen.


This came about because radiologists, not surgeons, developed the systems for digital X-ray, and their standard is to view the patient from the feet up, i.e. bottom to top, so the patient’s right is on the radiologist’s left. But the purpose of X-rays is not for radiologists to read them and get paid, but rather for surgeons and other physicians to use the X-rays for patient care.

I love my radiologist friends, but to adopt the radiologists’ standard over the operating surgeons’ is nightmarish. It is like setting airplane controls, not for the pilot, but to the standard of the repair crews. And although the young surgeons growing up with this may adapt to some degree, for those of us with over 20 years in the operating room, it is one more reason to retire early. Backwards X-rays add one more more level of uncertainty to an already complex situation.

Lets put this all together. Suppose there is a patient – a non verbal elderly man who is being taken to the operating room to have a right-sided brain tumor removed. In clinic the note was recorded in EMR erroneously by the resident physician as a left sided lesion. He recognized the error later and typed an addendum. But in the new world of medicine, where doctors are shift workers, he is not the one who prepares the patient for surgery. The next resident prepares the operative consent and paperwork for surgery, and he doesn’t find the addendum. So, he schedules the patient for a left-sided tumor removal. The patient – who cannot speak – cannot confirm verbally to the preoperative nurse that the procedure is on the right, a final check in most patients. And the surgeon, in the OR, who is used to having X-rays reflect the lesion as it really is in respect to left and right, sees the MRI of the tumor on the left of the screen, reads the notes and proceeds to explore the left side of the brain. Unfortunately, the tumor is on the right.

This happened very rarely in the old system. But, I expect an increase in frequency. Imagine if suddenly the auto industry changed the standard for steering wheels and now, when you turn the wheel to the right the car goes left. You may be OK most of the time, but when you are tired, anxious or just have a momentary lapse – boom. You revert to the old habits. It is human nature.

I would love to say that physicians are perfect, but we are human. As private individuals, physicians developed a system of medical practice over years that worked to prevent such errors, and overnight, the federal government replaced it with a top-down experimental system that has never been used or even tried.

Safety is everyone’s concern, but can only be practiced by those actually doing the patient care. And no one has more interest in your safety than your doctor. Instead of helping us, government mandates have made it harder and harder to be safe. In my hospital recently, an incident report was made after a patient did get to the Operating Room with a history that recorded the problem on the wrong side. Fortunately the correct operation was done.

More tragically, in Massachusetts, a patient received a kidney transplant from a patient who was Hepatitis C positive. Six physicians reviewed the donor’s chart and missed the fact that the donor was positive for the virus. In doing a so called “root cause analysis,” you have to either believe that six well-trained, seasoned specialists suddenly became carelessly incompetent, that the information was not readily available or that the information was presented in an unusable format. Although the uninitiated may think EMR makes everything readily available, the opposite is true. Electronic records present data in an impossible laundry list with no prioritizing and poor labeling.

We as an industry are an accident waiting to happen, in spite of pleas from physicians. It is no coincidence that the world-famous Barrows Neurologic Institute was one of the last hospitals to adopt an electronic X-ray system, or that surgical specialists have drug their feet on EMR in general.

Before I undergo any surgery on my own body, I will make sure to write “no” on the uninvolved side, and I carry a one-page medical summary of my diagnoses and medications wherever I go. With the government smart guys in charge, it is more critical than ever for patients to take an active role in safeguarding their own health.



segunda-feira, 8 de abril de 2013

New Study Identifies Better Solution for Itch


Shoppers spend more than $352 million annually on anti-itch remedies and they are faced with a wealth of options of over-the-counter products on store shelves.  A new study published in the international peer-reviewed journal, Acta Dermato-Venereologica, may just help itch sufferers zero in on the most effective remedies.Researchers at the Wake Forest School of Medicine compared a topical hydrogel containing aluminum acetate and strontium (sold commercially as TriCalm Hydrogel) head-to-head against two products commonly marketed for anti-itch; hydrocortisone and diphenhydramine (Benadryl 1%).  TriCalm was "significantly superior" to the other two over-the-counter anti-itch agents reducing both the peak intensity and duration of the subjects' itch, according to the results of the study.

"Managing itch, especially chronic itch, is challenging," said Gil Yosipovitch, MD, of the Dermatology Department at Wake Forest University and one of the study's authors. "Many of the typical over-the-counter remedies are not effective and what this study tells us is that TriCalm products are likely a more effective solution than other over-the-counter options."

The double blinded, vehicle-controlled study was looking specifically at non-histamine induced itches.  The researchers induced itch in the subjects using a tropical plant called cowhage typically used when studying non-histamine-induced itch, This type of itch is more related to chronic itch, where antihistamines do not have any anti-itch effect.

New TriCalm Hydrogel is steroid-free and is now available at Walgreens, CVS and other retailers.
TriCalm is a product of Cosmederm Bioscience, a specialty pharmaceutical company focused on dermatology and pain management. Drawing on years of laboratory research and published clinical work, Cosmederm develops products that target a wide variety of skin diseases and inflammatory conditions. With its portfolio of patented analgesic and anti-inflammatory compounds, Cosmederm has developed uniquely effective topical products ranging from cosmeceuticals and OTC drugs to a pipeline of prescription drug candidates. Cosmederm is the sole owner of COSMEDERM-7, a patented compound made from strontium that has been developed for dermatological applications. Cosmederm's product lines include TriCalm™, REFINITY™ Skin Solutions, and COSMEDERM SKIN SCIENCE™.

sexta-feira, 5 de abril de 2013

Experts gather for national melanoma summit


New Zealand and international experts in melanoma are gathering in Wellington on Friday 5 April to hear about recent developments, identify priorities for action and work more closely to reduce melanoma's incidence and impact.

New Zealand has one of the highest rates of melanoma skin cancer in the world, and over 300 people here die of melanoma each year. It is the most commonly registered cancer in men aged 25-44 and the second most commonly registered cancer in women aged 25-44.

Exposure to ultraviolet radiation (UV) from the sun is the primary cause of most melanomas and the risk of developing melanoma is strongly related to a history of one or more sunburns in childhood or adolescence.

Speakers include a number of New Zealanders based both here and overseas who are recognised internationally for their melanoma expertise. They include:
•    Professor David Elder, Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania. Professor Elder was recently involved in the development of international guidelines for lesion classification. Professor Elder's attendance is sponsored by the Genesis Oncology Trust.
•    Professor John Hawk, Emeritus Professor of Dermatology at St Thomas Hospital London and President, European Society for Photo Dermatology. Professor Hawk will address current trends in incidence and strategies for prevention of malignant melanoma. Professor Hawk's attendance is sponsored by the Cancer Society of New Zealand.
•    Dr Amanda Oakley, President of the New Zealand Dermatological Society and a specialist dermatologist based in Hamilton. Dr Oakley created and manages DermNet NZ, a vast online dermatological resource that receives more than one million visitors a month.
•    Dr Mary-Jane Sneyd, medical epidemiologist and Senior Research Fellow at the Department of Preventive and Social Medicine, University of Otago, Dunedin. Dr Sneyd has recently developed a New Zealand-specific prediction model to estimate an individual's risk of developing melanoma.  Dr Sneyd's attendance is sponsored by the Melanoma Foundation of New Zealand.
Melanoma Summit New Zealand 2013 is hosted by MelNet with support from the Health Promotion Agency, Cancer Society of New Zealand and Melanoma Foundation of New Zealand.
Further information:
The media is welcome to attend the summit. The keynote speakers are happy to be interviewed during the summit.  Please contact:
•    Jane Thompson on 021 883491, jane@cmq.co.nz beforehand to arrange an interview time, or
•    Lynne St.Clair-Chapman, Cancer Society National Communications Manager, on 5 April, the day of the summit, on 027 444 4150, lynne@cancer.org.nz.

Sponsors of the Melanoma Summit are: Roche Products, Cancer Society of New Zealand, Genesis Oncology Trust, Path Lab, Melanoma Foundation of New Zealand, Bristol-Myers Squibb, Abbott Molecular and New Zealand Dermatological Society.

More information about the Summit is available here: http://www.melanoma.org.nz/MelNet/News/Melanoma-Summit-2013/

quinta-feira, 4 de abril de 2013

Medicine by Text Message: Learning From the Third World


In the last decade, community health efforts have been made more effective by a simple insight: that time, money, and sometimes even lives can be saved through texting. At St. Gabriel's Hospital in Malawi, for example, 75 community health workers were trained to use text messages to communicate patient information, appointment reminders, and other health-related notifications to patients. Through this mobile health, or mHealth, initiative, the hospital saved approximately 2,048 hours of worker time and $3,000 in fuel, while doubling the capacity of the tuberculosis treatment program.

The case for this growing field in the developing world provokes some controversy, however. Tina Rosenberg, writing in The New York Times, argued recently that the field is in flux. "Roughly a decade after the start of mHealth ... these expectations are far from being met," she writes. "The delivery system is there. But we don't yet know what to deliver." Most of the testing done in the field, she goes on to argue, has focused on feasibility, not real health impacts. What's needed, many insist, is the use of randomized control trials -- the gold standard in science -- to help determine what actually helps the world's poor, versus what development workers and funders assume will.

After about a decade of attracting big philanthropic investment without enough measurable results, Uganda and South Africa have both put a hold on any new mHealth pilots in their countries. And as the developing world closes its doors, some nonprofits are turning their sights to the U.S. for further study. "While there is still much to do in low and middle income countries, there is a lot that can be learned and transferred from the experience of designing and implementing mHealth systems in resource constrained settings here in the U.S.," explained Patricia Mechael, the executive director of mHealth Alliance at the United Nations Foundation. If they can improve health outcomes through randomized control trials, they may be able to renew the philanthropic sectors' belief in the viability of the field.

And the U.S. could profit as well. Mobile interventions in prenatal care and chronic diseases, like diabetes, have already proven particularly successful, in large part because they are an easy way for people to take charge of their own health. Price Waterhouse Cooper estimates that mHealth interventions in the U.S. could save $10,000 per diabetic patient per year. The U.S. current spends $218 billion on diabetes every year.

Text messages have a wildly high "open and read" rate -- 97 percent versus 5 to 20 percent for email. What began as a field that mostly tackled approaches to improving care for HIV and AIDS patients has expanded its scope widely in the last few years. In 2011, a Lancet study reported that text messages to remind health workers in Kenya about the proper guidelines for malaria management improved care by 23.7 percent immediately after intervention and continuing to 24.5 percent six months later. One recent project even attempted to reduce depression among teenagers in Auckland, New Zealand using a cognitive behavioral therapy approach gone mobile; over three-quarters of participants viewed at least half of the uplifting text messages sent to them and 66.7 percent said it helped them in getting rid of negative thoughts.

Medic Mobile, a non-profit organization founded in 2009, has used technology -- like text messaging immunization reminders or providing apps with basic, life-saving information about prenatal care -- in over 20 countries on a wide variety of projects. Their efforts, thus far, have reached 3,500,000 people, or 700,000 households. This month and next, it will launch two U.S.-based initiatives.

One program, which will begin on April 18, aims to use text message reminders to increase appointment attendance among the largely immigrant, Latino population served by the San Mateo Medical Center. Those who opt-in will be able to confirm and reschedule appointments via text message. "These kinds of clinics currently have full-time staff devoted to calling and trying to track down patients," explained Josh Nesbit, the organization's CEO and co-founder. "We're trying to harness the power of asynchronicity to interact with as many people as possible in an efficient way."

The other project, launched on March 18, provides low-income, uninsured families with customized tracking and management software created in partnership with the Lucille Packard Children's Hospital at Stanford. The platform includes a reminder system for type I diabetic children and their caretakers, which can receive and recognize various types of SMS "check-ins" for blood sugar levels and respond appropriately to high or low values. Parts of it are structured like a game, where patients receive points as incentive for taking a proactive role in their care.

In addition to gaining the data they need to return to the developing world, the group is hoping to bring some of what they've learned over the last four years in the developing world to bear on these U.S.-focused projects -- global health experts are calling this increasingly common development "south to north" learning. Mechael explained, "Much of our work is focused on the enabling environment for mHealth in low and middle income countries, and frequently I find myself giving talks in the U.S. about what America can learn about mHealth from Africa, Asia, and Latin America."

As Medic Mobile embarks on the San Mateo Project, the tricky system was in the private, not public sector. They quickly learned that navigating monsoons in Bangladesh was a cake walk compared to navigating the deluge of bureaucracy to be found in an American health clinic. "It took us six months to just integrate our approach with their electronic filing system," said Nesbit. "That's really daunting to think about on a per project basis, so part of the work ahead is to figure out how to create mobile tools that aren't threatening to the electronic medical record providers, so we can just hand this off to clinics and they can do it on their own."

Nesbit predicts that text messaging is just one of many "south to north" learnings that will change the way health care is structured in the U.S. in the coming years; he also believes that the community health worker model, which revolutionized the quality of care in places like Rwanda and Ethiopia, will become increasingly common stateside.

To date, Medic Mobile has affected one million people's lives in Malawi, where the majority of people live off of less than $2 a day. Could the same kind of impact be possible in the U.S. context? This is part of what they are out to learn in the coming months. The results could have far-reaching consequences for the kinds of technological tools that we bring to bear on the U.S. health care crisis in the years ahead.

quarta-feira, 3 de abril de 2013

Matters of milk and medicine


Milk might not be all that we have been brought up to believe, claims author and naturopath N. K. Sharma

Breaking away from a common notion is not an easy task. With Milk: A Silent Killer Dr. N. K. Sharma wants the world to know that a glass of milk could turn into a nightmare for you and your loved ones.

Conventional wisdom, passed down over generations, holds that milk is good for health, and the slightly more suspicious claim that it will ensure good scores on the report card.

It is a source of calcium but could also be the reason for cancer. Sharma, a well known naturopath, has come up with a revised version of his book Milk, which was published in 1987. “Since my childhood I have been a lover of milk and been a sufferer too. I used to do medicines and yoga and never doubted why my ailing condition was not being cured,” he says.

A large intake of milk over several years can lead to cancer, as the magnesium it contains can get slowly deposited in the body.

The doctor also believes that prevention is better than cure and boasts proudly about he has shielded his family from any form of disease. “God has graced us with a healthy mind and body, nobody is born ill. It is we who deplete the condition of our body through our ignorance,” he says.“Disease is not natural, health is natural state of body; medicines should not become a lifestyle and it should be treated as a medicine only.”

But to shatter the common myth that has been here for ages is not an easy task. “We have to become the message. We know what is the right thing to do, we will certainly benefit from it later. We have been brought up to believe milk is good, it is high time for it to change,” he signs off.

segunda-feira, 1 de abril de 2013

Sunderland salon offers teenagers skin treatment in bid to curb suicide-linked acne drug

Teenagers with acne are being offered half-price 'blue-light' treatment at Pure Bliss on Sea Road in Fulwell. Teenagers with acne are being offered half-price 'blue-light' treatment at Pure Bliss on Sea Road in Fulwell.
A BEAUTY salon is offering alternative skin treatments in a bid to prevent teens taking a controversial drug.
Pure Bliss, Fulwell, is trialling a clear skin course to highlight the use of light therapy which can help cure acne.
Salon owner Lisa Watson said she wants parents and their children to know there are other treatments available before they take Roaccutane, which has been linked to depression, leading to suicide.
“I watched a programme a couple of months ago about the drug and was shocked to see that it has been linked to depression and young people committing suicide,” she said.
“It is available on prescription from a dermatologist and is only supposed to be given for the most severe cases of acne, but one of the people on the programme only had spots on his back and he was given it.
“We use Omnilux light therapy in the salon, and I wanted to start offering it half price to teens with severe acne to show that there are other treatments out there, and to make it accessible to them.”
The clear skin course uses a special blue light, which penetrates into the skin to stop the spread of the bacteria that causes acne.
A red light is also used to reduce inflammation of the skin and assist in its healing process.
“We do two sessions of the blue light, then one of the red, and repeat that,” said Lisa. “We’ll also offer other treatments – such as micro-dermabrasion – if the therapists think that is required.
“I don’t want to go against any doctors, I just want to let people know about alternative therapies.”
The course of eight treatments will be offered to teenagers with a severe case of acne for £145. The salon also gives skin care advice to stop acne.

Source: http://www.sunderlandecho.com/news/business/latest-news/sunderland-salon-offers-teenagers-skin-treatment-in-bid-to-curb-suicide-linked-acne-drug-1-5537771

quinta-feira, 28 de março de 2013

Experts gather for National Melanoma Summit

Thursday 28 March 2013, 4:23PM Media release from Melnet

New Zealand and international experts in melanoma will gather in Wellington on Friday 5 April for a national melanoma summit.

With the theme 'Connecting melanoma expertise in New Zealand' Melanoma Summit New Zealand 2013 is an opportunity for those working in all areas of melanoma control to hear about recent developments, identify priorities for action and work more closely to reduce melanoma's incidence and impact.

New Zealand has one of the highest rates of melanoma skin cancer in the world, and over 300 people here die of melanoma each year.

It is the most commonly registered cancer in men aged 25-44 and the second most commonly registered cancer in women aged 25-44.

Exposure to ultraviolet radiation (UV) from the sun is the primary cause of most melanomas and the risk of developing melanoma is strongly related to a history of one or more sunburns in childhood or adolescence.

The National Melanoma Summit is hosted by MelNet - with support from the Health Promotion Agency and sponsorship from other key stakeholders, such as the Cancer Society of New Zealand.

The media is welcome to attend the summit. The keynote speakers are happy to be interviewed during the summit.  Please contact:
•    Jane Thompson on 021 883491, jane@cmq.co.nz beforehand to arrange an interview time, or
•    Lynne St.Clair-Chapman, Cancer Society National Communications Manager, on 5 April, the day of the summit, on 027 444 4150, lynne@cancer.org.nz.
Keynote summit speakers include:
•    Professor David Elder, Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania. Professor Elder was recently involved in the development of international guidelines for lesion classification. Professor Elder's attendance is sponsored by the Genesis Oncology Trust.
•    Professor John Hawk, Emeritus Professor of Dermatology at St Thomas Hospital London and President, European Society for Photo Dermatology. Professor Hawk will address current trends in incidence and strategies for prevention of malignant melanoma. Professor Hawk's attendance is sponsored by the Cancer Society of New Zealand.
•    Dr Amanda Oakley, who is President of the New Zealand Dermatological Society and a specialist dermatologist based in Hamilton.  Dr Oakley created and manages DermNet NZ, a vast online dermatological resource that receives more than one million visitors a month.
•    Dr Mary-Jane Sneyd, medical epidemiologist and Senior Research Fellow at the Department of Preventive and Social Medicine, University of Otago, Dunedin. Dr Sneyd has recently developed a New Zealand-specific prediction model to estimate an individual's risk of developing melanoma.  Dr Sneyd's attendance is sponsored by the Melanoma Foundation of New Zealand.

Sponsors of the Melanoma Summit are Roche Products, Cancer Society of New Zealand, Genesis Oncology Trust, Path Lab, Melanoma Foundation of New Zealand, Bristol-Myers Squibb, Abbott Molecular and the New Zealand Dermatological Society.
More information about the Summit is available here: http://www.melanoma.org.nz/MelNet/News/Melanoma-Summit-2013/

quarta-feira, 27 de março de 2013

'The Dermatological Drugs Market Will Reach $24.4 Billion in 2015' Shows Visiongain Report

LONDON, March 8, 2013 /PRNewswire/ --

A new report by visiongain predicts that the world market for dermatological drugs will reach $24.4 billion in 2015. That revenue forecast and others appear in Dermatological Drugs: World Market Prospects 2013-2023, published in March 2013. Visiongain is a business information provider based in London, UK.
Visiongain forecasts that the global dermatological drugs market will grow steadily from 2013 to 2023. That market is a high-revenue sector with a high public and healthcare profile. Revenue growth will be stimulated by an increase in disease prevalence, a result of aging populations and effects linked with modern life. Dermatological diseases often have high patient burden, resulting in significant disruption of everyday activities. Consumers continue to demand improved treatment options from healthcare providers.
Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: "Growth in the market will be stimulated by new drugs and reformulations of existing products from 2013 onwards. The launch of treatments providing more efficacy, improved drug delivery, new dosing schedules and better-served patient populations will also drive market expansion. Visiongain believes that the psoriasis submarket will especially stimulate market growth. Biologic drugs, generating high revenue, will continue to dominate psoriasis treatments - a key element for market development. The emerging markets in India and China will also become important for dermatological medicines, driven by healthcare demand in those regions.
"The dermatologic drug market is broad, with scope for development in many areas. There is a high level of genericisation in acne and dermatitis markets. However, this will be countered through the launch of novel combination therapies. There will be opportunities in the infectious skin disease market, buoyed by increasing prevalence of skin and skin structure infections - a result of multidrug-resistant bacteria causing hospital and community acquired infections.
"In addition, a key issue facing physicians is patient adherence. For example, many topical psoriasis treatments are highly potent. However, treatment regimes can often be complicated and impractical for patients, leading to poor compliance and ultimately ineffective drugs. There are clear opportunities for drug developers to work closely with physicians and patients. These include the development of novel drug formulations and delivery technologies that are practical and patient friendly."
Visiongain's report shows revenue forecasts to 2023 at world market, therapeutic submarket, product and national level. It forecasts world sales for the following submarkets:
• Infectious skin disease
• Psoriasis
• Dermatitis
• Acne
• Other treatments.
That investigation also forecasts sales of 23 leading and recently launched drugs, including Cubicin, Zyvox, Humira, Enbrel, Stelara, Claravis, Epiduo and Protopic.
The analysis includes researching trends and forecasting revenues in leading national markets. Countries and regions analysed are the US, Japan, EU5 (Germany, the UK, France, Italy and Spain), China, India, Brazil and Russia (BRIC).
Dermatological Drugs: World Market Prospects 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the visiongain report Dermatological Drugs: World Market Prospects 2013-2023, please visit: http://www.visiongain.com/Report/993/Dermatological-Drugs-World-Market-Prospects-2013-2023
For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44-(0)20-7336-6100
Companies Listed
3SBio
Abbott Laboratories
Actavis
Affiinium
AiCuris
Allergan
Almirall
Amgen
Anacor Pharmaceuticals
AndroScience Corp
Anterios
ApoPharma
Apote
Apotex
Apotheca
Applied Genetics
Astellas Pharma
Astion
AstraZeneca
Asubio Pharma
Aurobindo Pharma
Ausio Pharmaceuticals
Basilea Pharmaceutica
Bayer
BergPharma
BioCryst Pharmaceuticals
Biofrontera Bioscience
Biofrontera Pharma GmbH
BioMAS
Biotest
Biovail
Birken
Braintree Laboratories
Bristol-Myers Squibb
British Association of Dermatologists
California Institute of Technology
Can-Fite BioPharma
Causa Research
Celgene Corporation
Cempra
Centocor Ortho Biotech
Cipher Pharma
Cipla
CollaGenex Pharmaceuticals
Cosmo Pharmaceuticals
Cubist Pharmaceuticals
Cutanea Life Sciences
Daiichi Sankyo
DAVA Pharmaceuticals
Dermik
Dermira
Dr. Reddy's Laboratories
Durata Therapeutics
DUSA Pharmaceuticals
Eisai
Eli Lilly
European Medicines Agency (EMA)
Foamix
Forest Laboratories
Forward-Pharma GmbH
Fougera
French Medicines Agency
Furiex Pharmaceuticals
G&E Herbal Biotechnology Co
G&W Labs
Galderma
Gene Signal International
Genzyme
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Graceway Pharmaceuticals
Gruenenthal
Hanwha Pharma
Health Canada
Heritage Pharmaceuticals
Immunex
Impax Pharmaceuticals
Incyte
Innovaderm Research
iNova Pharmaceuticals
Intercell
Intrepid Therapeutics
Isotechnika Pharma
Janssen
Janssen Biotech
Johnson & Johnson
KV Pharmaceuticals
LEO Pharma
Ligand Pharmaceuticals
Lupin Pharmaceuticals
Lux Biosciences
Maruho Co
Massachusetts General Hospital
Matrix Laboratories
Meda AB
Medici
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medicis
Medimetriks Pharmaceuticals
Merck & Co.
Merz Pharmaceuticals
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical Co
Morria Biopharmaceuticals
Mycenax Biotech
Mylan Pharmaceuticals
Nabriva Therapeutics
NanoBio Corporation
National Cancer Institute
National Institutes for Health (NIH)
NovaDigm Therapeutics
Novartis
Nycomed
Oplon-Pure Science
Par Pharmaceuticals
Paratek Pharmaceuticals
Perrigo
Pfizer
Photocure
Pierre Fabre Medicament
Pliva Hrvatska
PolyMedix
Promius Pharma
Provectus Pharmaceuticals
QuatRx Pharmaceuticals
Ranbaxy Pharmaceuticals
Rib-X Pharmaceuticals
Roche
Roxane Laboratories
Sandoz
Sanofi
Sanofi-Pasteur
Schering-Plough
Shinogi
Sol-gel Technologies
Star Pharma
Stiefel Laboratories
Takeda Pharmaceuticals
Targanta Therapeutics
Taro Pharmaceutical Industries
Teva Pharmaceutical Industries
The American Academy of Dermatology
The Brazilian Society of Dermatology
The Medicines Company
Theravance
Tolmar
Topica Pharmaceuticals
Trius Therapeutics
UCB
University of Cologne
US Department of Health and Human Services
US Food and Drug Administration (FDA)
Valeant Pharmaceuticals
Wake Forest University School of Medicine
Warner Chilcott
Watson Laboratories
Welichem Biotech
Wyeth
Xoma
Zalicus
Zurita Laboratorio Farmaceutico
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials and Automotive sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44-(0)207-336-6100

SOURCE Visiongain

terça-feira, 26 de março de 2013

Meladerm Skin Lightening Cream Provides Complete Skin Care Solution

Jawa Barat, Indonesia -- (SBWIRE) -- 03/25/2013 -- It is among everyone’s top priority to look beautiful, fresh and glowing as ever but it is not quite possible without the use of some sort of skin glowing cream. Well almost every other women use fairness and other skin treatment creams that could make them look prettier. However, it is evenly important that one should read out carefully about the ingredients used in the cream and read out some of the reviews to find out about its effectiveness before actually buying one.

Meladerm cream was launched into the market by Civant Skin Care, a well known company for producing high quality skin treatment products, back in 2003 almost a decade ago after 4 long years of research. The major purpose of Meladerm cream is to improve the skin tone and reduce blemishes. However these are not the only things that Meladerm treats but the cream also takes care of things like tanning, freckles, acne marks, old scars, damage to skin by sun and other dark areas of the skin.

The Meladerm cream is a complete skin treatment cream that fights almost every other day skin problem. One of the most inspiring and motivating things about Meladerm cream is that it is made up of traditional and natural ingredients and other formulas to make one fine and effective cream. However, the product does contain some artificial things as well but having said that, it doesn’t contain any potentially harmful substances like mercury, steroids, Paraben, etc.

The man behind the Civant Skin Care talked about Meladerm cream, “We started with the idea of an effective but safe formula for skin care. The idea was simple enough, but it took four extensive years of research and development to bring out the Meladerm cream.” As described by the owner itself that this cream became reality only after years of research by research and development team.

The owner of Civant Skin Care Added, “Even as I speak, our R&D team is working on improving the formula, making Meladerm cream the most advanced of its kind in the market today.” The use is fairly simple just like any other fairness and skin glowing cream, one need to apply Meladerm cream on the affected areas of the skin twice a day.

However, it is highly advised that pregnant women and women who belong to the nursing profession should avoid the use of Meladerm cream and whoever has any kind of skin disease should consult doctor before choosing to buy Meladerm cream. The result will solely depend on the skin conditions of an individual, although the cream has a higher success rate but one should read out this Meladerm review of many Meladerm reviews available out there before actually splashing the cash on a skin treatment cream.

For more information, head over to http://tipstobeauty.com/meladerm